Compare MOV & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOV | IVA |
|---|---|---|
| Founded | 1961 | 2011 |
| Country | United States | France |
| Employees | 1386 | 77 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 854.9M | 883.8M |
| IPO Year | N/A | N/A |
| Metric | MOV | IVA |
|---|---|---|
| Price | $37.58 | $3.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $31.50 | $16.20 |
| AVG Volume (30 Days) | 298.8K | ★ 1.3M |
| Earning Date | 05-28-2026 | 03-30-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $0.67 | $751.20 |
| P/E Ratio | $25.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $2.94 |
| 52 Week High | $39.85 | $7.98 |
| Indicator | MOV | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 47.55 |
| Support Level | $35.92 | $3.79 |
| Resistance Level | $39.20 | $4.67 |
| Average True Range (ATR) | 1.16 | 0.18 |
| MACD | -0.39 | 0.08 |
| Stochastic Oscillator | 31.50 | 90.32 |
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.